{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:45:41Z","timestamp":1787496341958,"version":"build-2736575974"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12883-016-0549-8","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T08:41:45Z","timestamp":1456303305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pain management strategies for neuropathic pain in Fabry disease - a systematic review"],"prefix":"10.1186","volume":"16","author":[{"given":"Y.","family":"Schuller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. E.","family":"Linthorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. E. M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. N.","family":"Van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Biegstraaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,24]]},"reference":[{"issue":"21","key":"549_CR1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","volume":"276","author":"RO Brady","year":"1967","unstructured":"Brady RO, et al. Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276(21):1163\u20137.","journal-title":"N Engl J Med"},{"key":"549_CR2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"549_CR3","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1006\/bbrc.1993.2659","volume":"197","author":"S Ishii","year":"1993","unstructured":"Ishii S, et al. Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem Biophys Res Commun. 1993;197(3):1585\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"549_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L Tol van der","year":"2014","unstructured":"van der Tol L, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1\u20139.","journal-title":"J Med Genet"},{"issue":"3","key":"549_CR5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","volume":"34","author":"A Mehta","year":"2004","unstructured":"Mehta A, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236\u201342.","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"549_CR6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/gim.2014.120","volume":"17","author":"DA Laney","year":"2015","unstructured":"Laney DA, et al. Fabry disease in infancy and early childhood: a systematic literature review. Genet Med. 2015;17(5):323\u201330.","journal-title":"Genet Med"},{"issue":"2","key":"549_CR7","first-page":"61","volume":"106","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R. Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy. Acta Neurol Belg. 2006;106(2):61\u20135.","journal-title":"Acta Neurol Belg"},{"issue":"2","key":"549_CR8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","volume":"106","author":"M Biegstraaten","year":"2012","unstructured":"Biegstraaten M, et al. Small fiber neuropathy in Fabry disease. Mol Genet Metab. 2012;106(2):135\u201341.","journal-title":"Mol Genet Metab"},{"key":"549_CR9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neulet.2015.01.084","volume":"594","author":"L Choi","year":"2015","unstructured":"Choi L, et al. The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain. Neurosci Lett. 2015;594:163\u20138.","journal-title":"Neurosci Lett"},{"issue":"5","key":"549_CR10","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/mus.10236","volume":"26","author":"CA Luciano","year":"2002","unstructured":"Luciano CA, et al. Physiological characterization of neuropathy in Fabry\u2019s disease. Muscle Nerve. 2002;26(5):622\u20139.","journal-title":"Muscle Nerve"},{"issue":"11","key":"549_CR11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","volume":"162","author":"M Ries","year":"2003","unstructured":"Ries M, et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr. 2003;162(11):767\u201372.","journal-title":"Eur J Pediatr"},{"issue":"4","key":"549_CR12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00000446-200104000-00019","volume":"101","author":"VL Stryker","year":"2001","unstructured":"Stryker VL, Kreps C. Fabry disease. Am J Nurs. 2001;101(4):39\u201344.","journal-title":"Am J Nurs"},{"issue":"439","key":"549_CR13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1651-2227.2002.tb03110.x","volume":"91","author":"R Schiffmann","year":"2002","unstructured":"Schiffmann R, Scott LJ. Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr Suppl. 2002;91(439):48\u201352.","journal-title":"Acta Paediatr Suppl"},{"issue":"5","key":"549_CR14","first-page":"773","volume":"64","author":"J Dersh","year":"2002","unstructured":"Dersh J, Polatin PB, Gatchel RJ. Chronic pain and psychopathology: research findings and theoretical considerations. Psychosom Med. 2002;64(5):773\u201386.","journal-title":"Psychosom Med"},{"issue":"4","key":"549_CR15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","volume":"11","author":"KF Gold","year":"2002","unstructured":"Gold KF, et al. Quality of life of patients with Fabry disease. Qual Life Res. 2002;11(4):317\u201327.","journal-title":"Qual Life Res"},{"issue":"6","key":"549_CR16","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10545-007-0708-6","volume":"30","author":"AL Cole","year":"2007","unstructured":"Cole AL, et al. Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis. 2007;30(6):943\u201351.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"549_CR17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AJP.0b013e318074c986","volume":"23","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey. Clin J Pain. 2007;23(6):535\u201342.","journal-title":"Clin J Pain"},{"issue":"12","key":"549_CR18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1445-5994.2002.00291.x","volume":"32","author":"J Galanos","year":"2002","unstructured":"Galanos J, et al. Clinical features of Fabry\u2019s disease in Australian patients. Intern Med J. 2002;32(12):575\u201384.","journal-title":"Intern Med J"},{"issue":"5","key":"549_CR19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","volume":"64","author":"RJ Hopkin","year":"2008","unstructured":"Hopkin RJ, et al. Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res. 2008;64(5):550\u20135.","journal-title":"Pediatr Res"},{"issue":"1-3","key":"549_CR20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(01)01312-7","volume":"429","author":"J MacDermot","year":"2001","unstructured":"MacDermot J, MacDermot KD. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol. 2001;429(1-3):121\u20135.","journal-title":"Eur J Pharmacol"},{"key":"549_CR21","first-page":"177","volume":"31","author":"D Wise","year":"1962","unstructured":"Wise D, Wallace HJ, Jellinek EH. Angiokeratoma corporis diffusum. A clinical study of eight affected families. Q J Med. 1962;31:177\u2013206.","journal-title":"Q J Med"},{"issue":"9","key":"549_CR22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/jnnp.2006.108464","volume":"78","author":"O Lidove","year":"2007","unstructured":"Lidove O, et al. Chronic meningitis and thalamic involvement in a woman: Fabry disease expanding phenotype. J Neurol Neurosurg Psychiatry. 2007;78(9):1007.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"227","key":"549_CR23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/adc.43.227.73","volume":"43","author":"AW Johnston","year":"1968","unstructured":"Johnston AW, Weller SD, Warland BJ. Angiokeratoma corporis diffusum. Some clinical aspects. Arch Dis Child. 1968;43(227):73\u20139.","journal-title":"Arch Dis Child"},{"issue":"1","key":"549_CR24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00685960","volume":"33","author":"N Fukuhara","year":"1975","unstructured":"Fukuhara N, et al. Fabry\u2019s disease on the mechanism of the peripheral nerve involvement. Acta Neuropathol. 1975;33(1):9\u201321.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"549_CR25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/21548331.1996.11443317","volume":"31","author":"R Hariharan","year":"1996","unstructured":"Hariharan R, Fred HL. Leg pain and kidney disease in a 38-year-old man. Hosp Pract (1995). 1996;31(7):119\u201320.","journal-title":"Hosp Pract (1995)"},{"issue":"5","key":"549_CR26","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/(SICI)1096-8628(19990219)82:5<436::AID-AJMG14>3.0.CO;2-X","volume":"82","author":"IE Knol","year":"1999","unstructured":"Knol IE, et al. Different phenotypic expression in relatives with fabry disease caused by a W226X mutation. Am J Med Genet. 1999;82(5):436\u20139.","journal-title":"Am J Med Genet"},{"issue":"9259","key":"549_CR27","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(05)71823-7","volume":"357","author":"MM Chowdhury","year":"2001","unstructured":"Chowdhury MM, Holt PJ. Pain in Anderson-Fabry\u2019s disease. Lancet. 2001;357(9259):887.","journal-title":"Lancet"},{"issue":"6","key":"549_CR28","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1046\/j.1365-2133.2001.04263.x","volume":"144","author":"MM Chowdhury","year":"2001","unstructured":"Chowdhury MM, Holt PJ. Burning fingers, but where is the fire? Br J Dermatol. 2001;144(6):1286.","journal-title":"Br J Dermatol"},{"issue":"9422","key":"549_CR29","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/S0140-6736(04)16254-5","volume":"363","author":"OA Bodamer","year":"2004","unstructured":"Bodamer OA, et al. Recurrent acroparaesthesia during febrile infections. Lancet. 2004;363(9422):1698.","journal-title":"Lancet"},{"issue":"1","key":"549_CR30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/mus.20130","volume":"31","author":"D Lacomis","year":"2005","unstructured":"Lacomis D, Roeske-Anderson L, Mathie L. Neuropathy and Fabry\u2019s disease. Muscle Nerve. 2005;31(1):102\u20137.","journal-title":"Muscle Nerve"},{"issue":"1","key":"549_CR31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","volume":"96","author":"U Ramaswami","year":"2007","unstructured":"Ramaswami U, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr. 2007;96(1):122\u20137.","journal-title":"Acta Paediatr"},{"issue":"4","key":"549_CR32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3928\/00904481-20090401-01","volume":"38","author":"J Charrow","year":"2009","unstructured":"Charrow J. A 14-year-old boy with pain in hands and feet. Pediatr Ann. 2009;38(4):190. 192.","journal-title":"Pediatr Ann"},{"issue":"10","key":"549_CR33","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3109\/14767050903580391","volume":"23","author":"E Parent","year":"2010","unstructured":"Parent E, et al. Fabry disease complicating pregnancy. J Matern Fetal Neonatal Med. 2010;23(10):1253\u20136.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"3","key":"549_CR34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-009-0211-y","volume":"31","author":"A Salviati","year":"2010","unstructured":"Salviati A, Burlina AP, Borsini W. Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy. Neurol Sci. 2010;31(3):299\u2013306.","journal-title":"Neurol Sci"},{"issue":"3","key":"549_CR35","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/acr.20385","volume":"63","author":"I Pagnini","year":"2011","unstructured":"Pagnini I, et al. Distal extremity pain as a presenting feature of Fabry\u2019s disease. Arthritis Care Res (Hoboken). 2011;63(3):390\u20135.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"549_CR36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11916-013-0365-4","volume":"17","author":"M Biegstraaten","year":"2013","unstructured":"Biegstraaten M et al. Fabry disease: a rare cause of neuropathic pain. Curr Pain Headache Rep. 2013;17(10):365.","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"549_CR37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00108-012-3204-5","volume":"54","author":"C Sommer","year":"2013","unstructured":"Sommer C, et al. Pain therapy for Fabry\u2019s disease. Internist (Berl). 2013;54(1):121\u20132. 124-30.","journal-title":"Internist (Berl)"},{"issue":"4","key":"549_CR38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1525-1470.2005.22411.x","volume":"22","author":"S Choudhury","year":"2005","unstructured":"Choudhury S, Meehan S, Shin HT. Fabry disease: an atypical presentation. Pediatr Dermatol. 2005;22(4):334\u20137.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"549_CR39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/archneur.63.3.453","volume":"63","author":"CS Nance","year":"2006","unstructured":"Nance CS, et al. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Arch Neurol. 2006;63(3):453\u20137.","journal-title":"Arch Neurol"},{"issue":"7","key":"549_CR40","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.clineuro.2012.11.003","volume":"115","author":"I Brabander De","year":"2013","unstructured":"De Brabander I, et al. Phenotypical characterization of alpha-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young. Clin Neurol Neurosurg. 2013;115(7):1088\u201393.","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"549_CR41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cge.12449","volume":"88","author":"BE Smid","year":"2015","unstructured":"Smid BE, et al. Diagnostic dilemmas in Fabry disease: a case series study on GLA mutations of unknown clinical significance. Clin Genet. 2015;88(2):161\u20136.","journal-title":"Clin Genet"},{"key":"549_CR42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/8904_2012_167","volume":"8","author":"W Terryn","year":"2013","unstructured":"Terryn W, et al. Questioning the Pathogenic Role of the GLA p.Ala143Thr \u201cMutation\u201d in Fabry Disease: Implications for Screening Studies and ERT. JIMD Rep. 2013;8:101\u20138.","journal-title":"JIMD Rep"},{"issue":"4","key":"549_CR43","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.39.4.598","volume":"39","author":"MR Filling-Katz","year":"1989","unstructured":"Filling-Katz MR, et al. Carbamazepine in Fabry\u2019s disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction. Neurology. 1989;39(4):598\u2013600.","journal-title":"Neurology"},{"issue":"3","key":"549_CR44","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0887-8994(95)00007-3","volume":"12","author":"KE Gordon","year":"1995","unstructured":"Gordon KE, Ludman MD, Finley GA. Successful treatment of painful crises of Fabry disease with low dose morphine. Pediatr Neurol. 1995;12(3):250\u20131.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"549_CR45","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0387-7604(12)80153-7","volume":"14","author":"M Inagaki","year":"1992","unstructured":"Inagaki M, et al. Relative hypoxia of the extremities in Fabry disease. Brain Dev. 1992;14(5):328\u201333.","journal-title":"Brain Dev"},{"issue":"3","key":"549_CR46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0887-8994(90)90067-B","volume":"6","author":"M Inagaki","year":"1990","unstructured":"Inagaki M, et al. Relief of chronic burning pain in Fabry disease with neurotropin. Pediatr Neurol. 1990;6(3):211\u20133.","journal-title":"Pediatr Neurol"},{"issue":"8","key":"549_CR47","first-page":"704","volume":"34","author":"G Lenoir","year":"1977","unstructured":"Lenoir G, et al. Fabry\u2019s disease. Carbamazepine therapy in acrodyniform syndrome. Arch Fr Pediatr. 1977;34(8):704\u201316.","journal-title":"Arch Fr Pediatr"},{"issue":"1","key":"549_CR48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/01.cnd.0000172992.73676.c2","volume":"7","author":"SN Lim","year":"2005","unstructured":"Lim SN, et al. Subtle Changes in Cutaneous Nerves and Sural Nerve Biopsy in a Patient With Fabry\u2019s Disease. J Clin Neuromuscul Dis. 2005;7(1):19\u201324.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"8","key":"549_CR49","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.23.8.871","volume":"23","author":"LA Lockman","year":"1973","unstructured":"Lockman LA, et al. Relief of pain of Fabry\u2019s disease by diphenylhydantoin. Neurology. 1973;23(8):871\u20135.","journal-title":"Neurology"},{"issue":"4","key":"549_CR50","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/BF02283120","volume":"11","author":"SO Paira","year":"1992","unstructured":"Paira SO, et al. Joint manifestations of Fabry\u2019s disease. Clin Rheumatol. 1992;11(4):562\u20135.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"549_CR51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3344\/kjp.2010.23.3.207","volume":"23","author":"KB Park","year":"2010","unstructured":"Park KB, et al. Early diagnosis of fabry disease in a patient with toe tip pain. Korean J Pain. 2010;23(3):207\u201310.","journal-title":"Korean J Pain"},{"issue":"1","key":"549_CR52","first-page":"69","volume":"62","author":"RB Patil","year":"2014","unstructured":"Patil RB, Joglekar VK. Teenager male with burning pain in extremities--suspect Fabry disease, 2 case reports. J Assoc Physicians India. 2014;62(1):69\u201371.","journal-title":"J Assoc Physicians India"},{"issue":"4","key":"549_CR53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1025127723729","volume":"26","author":"M Ries","year":"2003","unstructured":"Ries M, et al. Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis. 2003;26(4):413\u20134.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"549_CR54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0022-510X(73)90019-1","volume":"18","author":"H Shibasaki","year":"1973","unstructured":"Shibasaki H, et al. Carbamazepine for painful crises in Fabry\u2019s disease. J Neurol Sci. 1973;18(1):47\u201351.","journal-title":"J Neurol Sci"},{"issue":"50","key":"549_CR55","first-page":"2412","volume":"144","author":"PH Slee","year":"2000","unstructured":"Slee PH, van Boven LJ, Slee DS. Fabry disease: data from four families. Ned Tijdschr Geneeskd. 2000;144(50):2412\u20135.","journal-title":"Ned Tijdschr Geneeskd"},{"issue":"6","key":"549_CR56","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jmg.15.6.428","volume":"15","author":"MW Spence","year":"1978","unstructured":"Spence MW, et al. Angiokeratoma corporis diffusum (Anderson-Fabry disease) in a single large family in Nova Scotia. J Med Genet. 1978;15(6):428\u201334.","journal-title":"J Med Genet"},{"issue":"3","key":"549_CR57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF00688064","volume":"38","author":"FM Tome","year":"1977","unstructured":"Tome FM, Fardeau M, Lenoir G. Ultrastructure of muscle and sensory nerve in Fabry\u2019s disease. Acta Neuropathol. 1977;38(3):187\u201394.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"549_CR58","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00467-004-1462-8","volume":"19","author":"L Tumer","year":"2004","unstructured":"Tumer L, et al. The co-existence of Fabry and celiac diseases: a case report. Pediatr Nephrol. 2004;19(6):679\u201381.","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"549_CR59","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1034\/j.1399-0004.2003.00050.x","volume":"63","author":"CC Yang","year":"2003","unstructured":"Yang CC, et al. Two novel mutations in the alpha-galactosidase A gene in Chinese patients with Fabry disease. Clin Genet. 2003;63(3):205\u20139.","journal-title":"Clin Genet"},{"issue":"4","key":"549_CR60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/qjmed\/hch043","volume":"97","author":"A Chaudhuri","year":"2004","unstructured":"Chaudhuri A. Painful arm in syringomyelia and Fabry disease. QJM. 2004;97(4):241\u20132.","journal-title":"QJM"},{"issue":"11","key":"549_CR61","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2169\/internalmedicine.41.983","volume":"41","author":"K Asahi","year":"2002","unstructured":"Asahi K, et al. Fabry disease with few clinical signs and symptoms. Intern Med. 2002;41(11):983\u20135.","journal-title":"Intern Med"},{"issue":"21","key":"549_CR62","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1001\/jama.284.21.2771","volume":"284","author":"RO Brady","year":"2000","unstructured":"Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. Jama. 2000;284(21):2771\u20135.","journal-title":"Jama"},{"issue":"3","key":"549_CR63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1525-1470.1995.tb00161.x","volume":"12","author":"ED Shelley","year":"1995","unstructured":"Shelley ED, Shelley WB, Kurczynski TW. Painful fingers, heat intolerance, and telangiectases of the ear: easily ignored childhood signs of Fabry disease. Pediatr Dermatol. 1995;12(3):215\u20139.","journal-title":"Pediatr Dermatol"},{"issue":"7","key":"549_CR64","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/art.1780220715","volume":"22","author":"KJ Sheth","year":"1979","unstructured":"Sheth KJ, Bernhard GC. The arthropathy of Fabry disease. Arthritis Rheum. 1979;22(7):781\u20133.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"549_CR65","first-page":"595","volume":"163","author":"K Mills","year":"2004","unstructured":"Mills K, et al. Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease. Eur J Pediatr. 2004;163(10):595\u2013603.","journal-title":"Eur J Pediatr"},{"issue":"4","key":"549_CR66","first-page":"392","volume":"102","author":"B Duperrat","year":"1975","unstructured":"Duperrat B, et al. Proceedings: Fabry\u2019s disease, angiokeratomas present at birth. Effect of diphenylhydantoin on painful attacks. Ann Dermatol Syphiligr (Paris). 1975;102(4):392\u20133.","journal-title":"Ann Dermatol Syphiligr (Paris)"},{"issue":"3","key":"549_CR67","doi-asserted-by":"crossref","first-page":"166","DOI":"10.33588\/rn.4903.2009100","volume":"49","author":"JM Politei","year":"2009","unstructured":"Politei JM. Intravenous lidocaine as treatment for the painful episodes in Fabry\u2019s disease. Rev Neurol. 2009;49(3):166\u20137.","journal-title":"Rev Neurol"},{"key":"549_CR68","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2377-11-61","volume":"11","author":"AP Burlina","year":"2011","unstructured":"Burlina AP, et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol. 2011;11:61.","journal-title":"BMC Neurol"},{"key":"549_CR69","first-page":"CD009485","volume":"5","author":"F Birse","year":"2012","unstructured":"Birse F, Derry S, Moore RA. Phenytoin for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;5:CD009485.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"549_CR70","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1586\/ern.10.57","volume":"10","author":"DS Hill","year":"2010","unstructured":"Hill DS et al. Teratogenic effects of antiepileptic drugs. Expert Rev Neurother. 2010;10(6):943\u201359.","journal-title":"Expert Rev Neurother"},{"key":"549_CR71","unstructured":"www.farmacotherapeutischkompas.nl . [cited 2015 December 23rd]."},{"issue":"2","key":"549_CR72","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/acps.12042","volume":"127","author":"N Byatt","year":"2013","unstructured":"Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand. 2013;127(2):94\u2013114.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"549_CR73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","volume":"54","author":"MJ Brodie","year":"2013","unstructured":"Brodie MJ, et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54(1):11\u201327.","journal-title":"Epilepsia"},{"issue":"4","key":"549_CR74","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","volume":"43","author":"PN Patsalos","year":"2002","unstructured":"Patsalos PN, et al. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43(4):365\u201385.","journal-title":"Epilepsia"},{"issue":"3","key":"549_CR75","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","volume":"61","author":"E Perucca","year":"2006","unstructured":"Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246\u201355.","journal-title":"Br J Clin Pharmacol"},{"issue":"3 Suppl","key":"549_CR76","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","volume":"85","author":"RH Dworkin","year":"2010","unstructured":"Dworkin RH, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3\u2013S14.","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"549_CR77","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/pch\/12.9.741","volume":"12","author":"OC Snead","year":"2007","unstructured":"Snead OC, Donner EJ. A new generation of anticonvulsants for the treatment of epilepsy in children. Paediatr Child Health. 2007;12(9):741\u20134.","journal-title":"Paediatr Child Health"},{"issue":"3","key":"549_CR78","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0304-3959(03)00330-0","volume":"106","author":"EJ Chesler","year":"2003","unstructured":"Chesler EJ, et al. Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. Pain. 2003;106(3):325\u201335.","journal-title":"Pain"},{"issue":"3","key":"549_CR79","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","volume":"132","author":"RH Dworkin","year":"2007","unstructured":"Dworkin RH, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237\u201351.","journal-title":"Pain"},{"issue":"1","key":"549_CR80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/jpm.2006.9.29","volume":"9","author":"J Raskin","year":"2006","unstructured":"Raskin J, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med. 2006;9(1):29\u201340.","journal-title":"J Palliat Med"},{"issue":"2","key":"549_CR81","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"3 Suppl","key":"549_CR82","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.4065\/mcp.2009.0647","volume":"85","author":"GA Walco","year":"2010","unstructured":"Walco GA, et al. Neuropathic pain in children: Special considerations. Mayo Clin Proc. 2010;85(3 Suppl):S33\u201341.","journal-title":"Mayo Clin Proc"},{"key":"549_CR83","unstructured":"WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. 2012: France. p. 51-52."},{"issue":"2","key":"549_CR84","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2015.10.007","volume":"117","author":"RJ Hopkin","year":"2016","unstructured":"Hopkin RJ, et al. The management and treatment of children with Fabry disease: A United States-based perspective. Mol Genet Metab. 2016;117(2):104\u201313.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"549_CR85","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s11916-011-0181-7","volume":"15","author":"A Hovaguimian","year":"2011","unstructured":"Hovaguimian A, Gibbons CH. Diagnosis and treatment of pain in small-fiber neuropathy. Curr Pain Headache Rep. 2011;15(3):193\u2013200.","journal-title":"Curr Pain Headache Rep"},{"issue":"21","key":"549_CR86","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743\u20139.","journal-title":"JAMA"},{"issue":"1","key":"549_CR87","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, et al. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345(1):9\u201316.","journal-title":"N Engl J Med"},{"issue":"7","key":"549_CR88","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","volume":"2","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg. PLoS One. 2007;2(7):e598.","journal-title":"PLoS One"},{"issue":"10","key":"549_CR89","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/AJP.0000000000000041","volume":"30","author":"N Uceyler","year":"2014","unstructured":"Uceyler N, et al. Characterization of Pain in Fabry Disease. Clin J Pain. 2014;30(10):915\u201320.","journal-title":"Clin J Pain"},{"issue":"1","key":"549_CR90","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004;75(1):65\u201374.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"549_CR91","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","volume":"118","author":"M Ries","year":"2006","unstructured":"Ries M, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics. 2006;118(3):924\u201332.","journal-title":"Pediatrics"}],"updated-by":[{"DOI":"10.1186\/s12883-016-0590-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,5,16]],"date-time":"2016-05-16T00:00:00Z","timestamp":1463356800000}}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-016-0549-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T10:03:19Z","timestamp":1748772199000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2377\/16\/25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,24]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1186\/s12883-016-0549-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,24]]},"article-number":"25"}}